10-Q · May 14, 2026
GeoVax's latest 10-Q filing reflects a notable shift in performance, with the company reporting a surprising positive EPS of 1.85 compared to a heavy loss in previous quarters. However, revenue remains at $0 due to the…
Earnings analysis · 10-Q
GOVX earnings analysis
Filed July 27, 2026 · Our reading of the company's report
The latest report
GeoVax reported Q2 2026 revenue of $0, down from $852,282 a year earlier as BARDA contract revenue ended; gross and operating margins are not meaningful because there was no revenue. Cost reductions narrowed Q2 net loss…
Read full summary
GeoVax reported Q2 2026 revenue of $0, down from $852,282 a year earlier as BARDA contract revenue ended; gross and operating margins are not meaningful because there was no revenue. Cost reductions narrowed Q2 net loss by $943,205 to $4,426,578 and reduced six-month operating cash burn to $7,195,824, but the company remains dependent on equity and warrant financings. Cash of $3,143,422 is expected to fund operations only into September 2026, and management continues to disclose substantial doubt about going concern, compounded by potential Nasdaq delisting exposure.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Operating loss narrowed 18% year over year
Q2 operating loss narrowed by $976,834 year over year to $4,442,072 from $5,418,906, as total operating expenses declined $1,829,116 to $4,442,072.
-
Material reduction in operating expenses
R&D expense fell 34.2% to $3,110,508 from $4,728,998, while G&A declined 13.7% to $1,331,564 from $1,542,190.
-
Cash burn improved versus prior year
Six-month operating cash use improved $3,104,254 to $7,195,824 from $10,300,078. Investing cash flow was $0, implying free cash flow of negative $7,195,824 for the six-month period.
-
Financings modestly increased cash
Cash and equivalents rose $57,681 from $3,085,741 at December 31, 2025 to $3,143,422 at June 30, 2026, supported by $7,253,505 of six-month financing cash inflow.
-
GEO-MVA Phase 3 planned for late 2026
Management intends to bypass Phase 1 and 2 studies and initiate GEO-MVA's Phase 3 study in late 2026, after EMA scientific advice received in May 2025.
What to watch
-
BARDA revenue has fully lapsed
Government-contract revenue fell to $0 in Q2 2026 from $852,282 in Q2 2025, and six-month revenue fell to $0 from $2,489,145 after BARDA terminated the contract in April 2025.
-
Near-term liquidity runway and going concern
Cash was $3,143,422 at June 30, 2026 and management says it is sufficient only into September 2026; working capital declined $1,915,139 to $1,462,811 from $3,377,950 at year-end. The company explicitly says substantial doubt exists about its ability to continue as a going concern.
-
Reliance on dilutive external financing
The company funded operations with $7,253,505 of six-month financing inflows, principally common-stock and warrant offerings, while operating cash use was $7,195,824. Management states additional equity sales would dilute stockholders.
-
New Nasdaq market-value delisting risk
A new Nasdaq requirement approved July 22, 2026 requires at least $5 million in market value of listed securities; a value below that threshold for 30 consecutive trading days would result in immediate delisting without a cure period. Management says its common stock trades near the $5 million threshold.
-
Pipeline advancement may accelerate cash burn
Management expects R&D spending to increase as it advances planned GEO-MVA and Gedeptin clinical programs, despite six-month operating cash use already totaling $7,195,824 and no product revenue to date.
Management's outlook
No quantitative revenue or EPS guidance was provided. Management expects to initiate the GEO-MVA Phase 3 study in late 2026 and targets Gedeptin Phase 2 trial initiation in 2027; it states that existing cash is sufficient only into September 2026.
Earlier filings 4
10-K · April 15, 2026
GeoVax is a clinical-stage vaccine and immunotherapy company prioritizing GEO-MVA (MVA-based mpox/smallpox vaccine) with a planned pivotal Phase 3 start in H2 2026 and multiple Phase 2 programs for GEO-CM04S1 and…
10-K · March 27, 2025
GeoVax (GOVX) is a clinical-stage vaccine and immunotherapy company with a BARDA-funded program (ATI‑RRPV) advancing its next‑generation COVID vaccine GEO‑CM04S1 into a planned 10,000‑patient Phase 2b trial (study…
10-Q · November 12, 2024
GeoVax recognized $2,789,484 of BARDA contract revenue in Q3 2024 (Q3 2023: $0), narrowing its quarter loss to $(5,815,468) or $(0.91) per share versus $(8,408,818) or $(4.75) in Q3 2023. Operating loss improved to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.